Prestige Consumer Healthcare Inc. ($PBH) reported a revenue decline in its fiscal third quarter due to a supply disruption at its Clear Eyes brand, resulting in a 4% drop in quarterly sales. The disruption, which was caused by a manufacturing issue, weighed on the company’s overall performance and led to a reduction in its price target by Canaccord to $86 from $88, with a maintained Buy rating on the shares.
The supply disruption at Clear Eyes, a key brand for $PBH, was a significant factor in the company’s revenue decline. Clear Eyes is a leading brand in the eye care segment, and the disruption affected the company’s ability to meet demand. According to Canaccord, the reduction in price target was due to the expected impact of the supply disruption on $PBH’s future sales.
$PBH’s fiscal third-quarter results showed a decline in revenue, with sales dropping to $241.8 million from $252.1 million in the same period last year. The company’s net income also declined, falling to $34.6 million from $41.4 million in the prior year. The decline in sales and net income was largely attributed to the supply disruption at Clear Eyes, which accounted for approximately 20% of the company’s total sales.
The market reaction to $PBH’s quarterly results was mixed, with some analysts expressing concern over the supply disruption and its impact on future sales. However, others noted that the company’s diversified portfolio and strong brand presence would help mitigate the effects of the disruption. Prestige Consumer Healthcare Inc. has a history of delivering strong results, and investors are waiting to see how the company will recover from the supply disruption.
The following table summarizes $PBH’s key metrics:
| Metric | Fiscal Q3 | Prior Year |
|---|---|---|
| Revenue | $241.8 million | $252.1 million |
| Net Income | $34.6 million | $41.4 million |
| Gross Margin | 54.1% | 55.3% |
Looking ahead, $PBH is expected to focus on resolving the supply disruption at Clear Eyes and restoring sales growth. The company’s diversified portfolio and strong brand presence are expected to help mitigate the effects of the disruption, but investors will be closely watching the company’s progress in the coming quarters.
⚡ Why it matters: The supply disruption at Clear Eyes has significant implications for $PBH’s future sales and revenue growth. The company’s ability to resolve the disruption and restore sales growth will be critical to its overall performance.
📊 By the numbers:
Revenue decline: 4%
Net income decline: 15.8%
Gross margin decline: 1.2%
🔗 Source: TheFly*
